Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
EBioMedicine ; 79: 103993, 2022 May.
Article in English | MEDLINE | ID: covidwho-1783294

ABSTRACT

The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, prevent disease, or accelerate TB treatment. These vaccines are of different types, and designed to replace BCG, or to boost immunity following BCG vaccination. This viewpoint discusses why, when it has been possible to develop new vaccines for SARS-CoV-2 so quickly, it is taking so long to develop new tuberculosis vaccines.


Subject(s)
COVID-19 , Mycobacterium bovis , Mycobacterium tuberculosis , Tuberculosis Vaccines , BCG Vaccine/therapeutic use , COVID-19/prevention & control , COVID-19 Vaccines , Humans , SARS-CoV-2 , Tuberculosis Vaccines/therapeutic use , Vaccination
SELECTION OF CITATIONS
SEARCH DETAIL